Arteris (AIP) director Janac records 40,000-share 10b5-1 stock sale

Rhea-AI Filing Summary

Arteris, Inc. director K. Charles Janac reported an indirect sale of company stock executed under a pre-arranged trading plan. On December 4, 2025, an entity he manages, Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock at a weighted average price of $16.4618 per share under a Rule 10b5-1 plan adopted on March 5, 2025. Following this transaction, Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.

Insider Trade Summary

Net Seller: 40,000 shares ($658,472)

Net Sell 1 txn

Insider Bayview Legacy, LLC

Role 10% Owner

Sold 40,000 shs ($658K)

Type	Security	Shares	Price	Value
Sale	Common Stock	40,000	$16.4618	$658K

Holdings After Transaction: Common Stock — 9,599,071 shares (Indirect, See Footnote)

Footnotes (1)

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025. K. Charles Janac, in his individual capacity, has separately filed a Form 4 on the date hereof reporting the same transaction given his beneficial ownership of the reported security through Bayview Legacy, LLC, which he controls as its manager. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.65 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. K. Charles Janac is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power over the shares beneficially owned by Bayview Legacy, LLC.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bayview Legacy, LLC

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		S(1)(2)		40,000	D	$16.4618(3)	9,599,071	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025.

2. K. Charles Janac, in his individual capacity, has separately filed a Form 4 on the date hereof reporting the same transaction given his beneficial ownership of the reported security through Bayview Legacy, LLC, which he controls as its manager.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.25 to $16.65 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. K. Charles Janac is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power over the shares beneficially owned by Bayview Legacy, LLC.

Remarks:

	/s/ K. Charles Janac	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transaction did Arteris (AIP) disclose for K. Charles Janac?

Arteris disclosed that director K. Charles Janac, through Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock in a reported transaction.

On what date and at what price were the Arteris (AIP) shares sold by K. Charles Janac?

The sale occurred on December 4, 2025 at a weighted average price of $16.4618 per share, with individual trades ranging from $16.25 to $16.65.

How many Arteris (AIP) shares does K. Charles Janac beneficially own after the reported sale?

After the reported sale, K. Charles Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.

Was the Arteris (AIP) insider sale made under a Rule 10b5-1 trading plan?

Yes. The transaction was made pursuant to a Rule 10b5-1 trading plan that was adopted by K. Charles Janac on March 5, 2025.

What is Bayview Legacy, LLC’s role in K. Charles Janac’s Arteris (AIP) holdings?

Bayview Legacy, LLC holds the Arteris shares, and K. Charles Janac, as its manager, is deemed to have voting and dispositive power over those shares.

Does K. Charles Janac have another report related to this Arteris (AIP) transaction?

Yes. He has separately filed a report in his individual capacity for the same transaction due to his beneficial ownership of the shares through Bayview Legacy, LLC.